DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYMBALTA

« Back to Dashboard

Clinical Trials for Cymbalta

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00105989	Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder	Completed	Boehringer Ingelheim	Phase 3	The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00105989	Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder	Completed	Eli Lilly and Company	Phase 3	The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00114127	Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome	Completed	Massachusetts General Hospital	Phase 3	The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
NCT00177671	Antidepressant Medication Plus Donepezil for Treating Late-life Depression	Completed	National Institute of Mental Health (NIMH)	Phase 4	This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00177671	Antidepressant Medication Plus Donepezil for Treating Late-life Depression	Completed	University of Pittsburgh	Phase 4	This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00185575	Duloxetine for the Treatment of Dysthymia	Completed	Eli Lilly and Company	N/A	The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

Clinical Trial Conditions for Cymbalta

Condition Name

Condition Name for Cymbalta
Intervention	Trials
Major Depressive Disorder	17
Depression	13
Fibromyalgia	7
Generalized Anxiety Disorder	5

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cymbalta
Intervention	Trials
Depression	38
Depressive Disorder	36
Depressive Disorder, Major	26
Disease	23

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cymbalta

Trials by Country

Trials by Country for Cymbalta
Location	Trials
United States	406
Canada	26
United Kingdom	11
Germany	10
France	9

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cymbalta
Location	Trials
New York	24
California	22
Florida	21
Ohio	20
Texas	18

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cymbalta

Clinical Trial Phase

Clinical Trial Phase for Cymbalta
Clinical Trial Phase	Trials
Phase 4	40
Phase 3	32
Phase 2/Phase 3	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cymbalta
Clinical Trial Phase	Trials
Completed	75
Recruiting	16
Terminated	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cymbalta

Sponsor Name

Sponsor Name for Cymbalta
Sponsor	Trials
Eli Lilly and Company	58
Boehringer Ingelheim	7
Shionogi	7

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cymbalta
Sponsor	Trials
Industry	82
Other	76
NIH	8

Export unavailable in trial.
Subscribe for complete access.